Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tinengotinib - TransThera Biosciences

Next Previous
Drug Profile

Tinengotinib - TransThera Biosciences

Alternative Names: TT 00420; Yochanra

Latest Information Update: 11 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TransThera Biosciences
  • Class 3-ring heterocyclic compounds; Antineoplastics; Chlorobenzenes; Morpholines; Pyrazoles; Pyridones; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Fibroblast growth factor receptor antagonists; Janus kinase inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Biliary cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Cholangiocarcinoma
  • Phase II HER2 negative breast cancer; Liver cancer
  • Phase I/II Prostate cancer; Solid tumours
  • No development reported Triple negative breast cancer

Most Recent Events

  • 07 Aug 2026 Registered for Cholangiocarcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) - First global approval
  • 17 Jul 2026 Nanjing Yaojie Ankang Biotechnology initiates a phase I drug-drug interaction trial in Solid tumours in China (CTR20262469) (700395787)
  • 02 Jul 2026 TransThera Sciences completes the enrolment from its Phase-III clinical trials in Cholangiocarcinoma (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in US, Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Portugal, South Korea, Taiwan, Spain and UK (PO) (NCT05948475)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top